Form 4: ACELYRIN Director Reports Share and Option Conversion Following Merger with Alumis Subsidiary

A recent SEC Form 4 filing reveals that Daniel J. Becker, a director at ACELYRIN, Inc., has converted all his common stock and stock options into shares of Alumis, Inc. common stock as a result of ACELYRIN's merger into a wholly-owned subsidiary of Alumis on May 21, 2025.

Summary

• Daniel J. Becker, a director of ACELYRIN, Inc. (SLRN), reported changes in his beneficial ownership following the merger of ACELYRIN into Arrow Merger Sub, Inc., a wholly-owned subsidiary of Alumis, Inc. (Parent), effective May 21, 2025.
• At the effective time of the merger, each share of ACELYRIN common stock was converted into the right to receive 0.4814 shares of Alumis, Inc. voting common stock, with cash in lieu of fractional shares.
• Mr. Becker disposed of 2,999 shares of ACELYRIN common stock, resulting in zero direct beneficial ownership of ACELYRIN common stock post-merger.
• Two director stock options, one for 23,243 shares with an exercise price of $18.00 and another for 92,158 shares with an exercise price of $4.46, were also disposed of as ACELYRIN options.
• These stock options were assumed by Alumis, Inc. and converted into options to purchase Alumis Common Stock, adjusted by the 0.4814 exchange ratio and a corresponding adjustment to the exercise price.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The document is neutral in tone, reporting a factual transaction (merger completion) and its impact on a director's holdings. The merger itself could be seen as a positive strategic event for the company, but the Form 4 merely reports the mechanics of share conversion, which is an expected outcome of such an event.

Positives

• The merger allows ACELYRIN shareholders, including Director Becker, to receive shares in Alumis, Inc., potentially offering continued exposure to the combined entity's future growth.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and systematic approach to the disposition of securities.

Negatives

• Director Becker no longer directly holds common stock or options in ACELYRIN, Inc., as it has become a wholly-owned subsidiary of Alumis, Inc.

Future Outlook

The document primarily reports a past transaction (merger completion) and its immediate impact on a director's holdings. It does not provide forward-looking statements or guidance regarding the future performance of Alumis, Inc. or the former ACELYRIN operations, beyond the continued vesting schedule of converted options.

Industry Context

This Form 4 filing reflects the finalization of a merger transaction in the biotechnology or pharmaceutical sector, where ACELYRIN, Inc. has been acquired by Alumis, Inc. Such consolidation is a common trend in the industry, driven by strategic portfolio alignment, pipeline synergies, or market positioning. The acquisition of ACELYRIN by Alumis suggests a strategic move by Alumis to integrate ACELYRIN's assets or capabilities into its own operations, potentially expanding its therapeutic areas or strengthening its market presence.

Stakeholder Impact

• Shareholders (former ACELYRIN): Their shares were converted into Alumis, Inc. common stock, changing their investment vehicle and future prospects from ACELYRIN to Alumis.
• Employees (former ACELYRIN): Stock options held by employees (represented by the director's options) were converted into Alumis options, maintaining their equity incentives within the new parent company structure.

Next Steps

• Continued service of Daniel J. Becker as a director for the vesting of his converted stock options.
• Future reporting by Daniel J. Becker on Form 4 for any subsequent transactions involving Alumis, Inc. common stock or options.

Key Dates

Keywords

ACELYRIN, SLRN, Alumis, Merger, Form 4, Beneficial Ownership, Stock Options, Director, Equity Conversion, Rule 10b5-1